

大阪大学老年学研究会 第3回小講演

From epidemiology to clinical trials: What's hot in dementia research?

Prof. Hiroko Dodge

Associate Professor of Neurology,
Oregon Health & Science University

Kevreson Research Professor of Neurology,
University of Michigan, Ann Arbor, MI



主催： 大阪大学老年学研究会 事務局：人間科学研究科 臨床死生学・老年行動学研究分野

日時

2015/6/4

場所

人間科学研究科
東館1階105

時間

午後6時-8時

入場無料 事前申し込み不要

問い合わせ ☎ Gerontology.Osaka@gmail.com

HIROKO DODGE

Associate Professor of Neurology,
Oregon Health & Science University

Kevreson Research Professor of Neurology,
University of Michigan, Ann Arbor, MI

SPEAKER BIO

Hiroko Dodge is the Milton and Kevreson Research Professor of Neurology at University of Michigan, Ann Arbor, USA, and Associate Professor of Neurology at Oregon Health & Science University, Portland, Oregon, USA. She jointly directs NIH-funded Layton Aging and Alzheimer's Disease Center at Oregon Health & Science University and Michigan Alzheimer's Disease Center at University of Michigan. She also serves as the Adjunct Professor at the Department of Epidemiology at the University of Pittsburgh, USA and at the Shiga University of Medical Sciences in Japan. She is an internationally recognized gerontologist and her work covers a wide range of research areas including: Epidemiology of Dementia, longitudinal data analyses, application of demographic methods to clinical studies, and pharmacological and non-pharmacological prevention trials.

ABSTRACT

The focus of dementia research shifted from risk factors of dementia during 1990s, to Mild Cognitive Impairment in early 2000s, and more recently, to early identification of dementia during pre-symptomatic phase. I will first discuss the recent hot topics in epidemiology of dementia. Then I will move to recent prevention studies where detecting early signs of Alzheimer's disease (AD) and mild cognitive impairment (MCI) is becoming increasingly important. I will introduce in-home activity monitoring projects conducted at Oregon Health & Science University, which were aimed to achieve cost-effective clinical trials and derive maximum benefit from currently available treatment strategies.

DISCLOSURE

Nothing to disclose